Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Analysts Unconvinced By Sanofi Best-In-Class Claims For Sarclisa

Much Ground To Make Up On J&J's Darzalex

Executive Summary

Sanofi presented new data at a post-ASCO briefing to back its claim that Sarclisa can become the anti-CD38 of choice for the treatment of multiple myeloma ahead of Darzalex. The investment community is not so sure.

You may also be interested in...



Sanofi Is ‘Working On’ Resolving England’s Sarclisa Funding Concerns

NICE is not yet convinced that Sanofi’s recently approved combination treatment for relapsed or refractory multiple myeloma is value for money. Temporary funding under the Cancer Drugs Fund has also been ruled out.

ASCO 2020: BCMA CAR-T Race Heats Up Between Bristol And Janssen

The gap between potential approvals for Bristol’s ide-cel and Janssen’s JNJ-4528 has narrowed as both CAR-T therapies show high response rates in multiple myeloma – and as bispecific antibodies, including Janssen’s teclistamab, edge into the space.

Genmab Cash Pile To Grow With Another Darzalex OK

The Danish biotech will be getting more revenues from its J&J-partnered multiple myeloma blockbuster following a new US approval. Analysts are impressed with the way Genmab is spending the money.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131511

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel